Subj ect Index. For abbreviations see p.4 (lipids), p.5 (lipoproteins), p.202 (enzymes)

Size: px

Start display at page:

Download "Subj ect Index. For abbreviations see p.4 (lipids), p.5 (lipoproteins), p.202 (enzymes)"

Sibyl Nelson
5 years ago
Views:

1 Subj ect Index For abbreviations see p.4 (lipids), p.5 (lipoproteins), p.202 (enzymes) A absorption, intestinal 48-63, 66,77,78 ACAT-enzyme 187,188,192,197, 198,203 acetate 66,67,152,158,160,173 acetone-butanol powders 203 acyl CoA 141,161,180,188,207 acyl CoA carboxylases acyl CoA transferases 180, 207 adaptation, eye 213, 223 adipose tissue 115 ADP 244 age differences 88,90-95 albumin 72,163,192,195 alpha-lipoproteins 6,16,20,41, 72,127,128 amino acid composition, apoproteins 22 AMP, see camp amphiphatic helices 37 amphiphilic molecules 133 anemia 41 angiography 237 aorta 28,89,160,163,187,191, 195, see also arterial apoa subfractions 21-27,36-41 apoc-i apod 37 apoe 38 apolopoproteins 5,6,11,20-24, 27,36,38 arachidonic acid 4,107,113,245 arginine-rich protein 38 arterenol 244 arterial wall 29,99, , , , c hoi est e ry 1 est e r s 1 1 2, 1 9 4, ,218,220 lip i d me tab 0 li s m 1 5 8, 1 88, 189,201 atherogenic diet 191,192,194, ,218,220 atheroma grade 141,146,147, 195 atherosclerosis, human 11,12, 20,28,34,98,99,125,141, 160,194,230,233, , 247 -blood flow , , -risk factors 28,98,99,247 atherolsclerosis, experimental 11,20,30,49,123,140,141, 160,187, ,211,212 prevention 141,195, regression 30,34,41,196, atherosclerotic lesions 28,30, 140,157, , 182, 187, 195,196, B baboon 21-23,27,187,192,195, 197,212 behaviour 214 betalipoproteins 6,16,20,29, 72,127,217 bile acids 72,189,192,212, 229 bile cannulation 63,78 binding, lipid-protein 20, blood-brain-barrier 66,76

2 250 blood, flow properties , , viscosity 30, ,237, 243 brain 53,58,74-76,89 c camp , 120 caolin 244 capillaries 228,229,234 carbohydrate 17,18,98-100, 107,112 cerebral blood flow 237, cephalins, see PE chain length of FA in lipids 24,28,87,205 chain length elongation 141, 171 chicken 212 chimpanzee 17-19,21-23 choles tasis 41 cholesterol 17,34,35,87,88, 127,187,189,197,201, arterial wall ,161,168, es terification 40,131,141, 162,194,198,203 lipoproteins 35,36,38,133, membranes 91 perifibrous lipid 161 plasma 11,13,28,39,99,100, 128,141,144,195,197 - / PL ratio 13,15,17,127,128 cholesteryl esters 4,27,28,35, 41,100,107,127,133,135,144, 187,201,203 arterial synthesis 152,161, 162,201,204,206 arterial turnover 39,40, ,156,160,161,179,183, 188,193,201,203,206,212 lipoproteins 35,38 synthesis 37,38,151 Tangier disease 39 transesterification 39,73, 136,208 cholesterylesterase, see ChEhydrolase cholesterylesterhydrolase 28, 131,187,188,189,192,198, 202 cholesterylester synthetase 28, 131, 188,189,192, 198 ChE synthetase / hydrolase ratio 192,193 cholesteryllinoleate 128,131, 134,161,206,207 cholesteryloleate 160,188,201, 202,204,206,207 cholesteryl palmitate 131,201, 202,206,207 cholic acid 192,212 choline 37,55,66,67 chromatography 11,21,27,41,42, 49,58,59,69,81,98,100,133, 135,190,213 chylomicronemia 39 chylomicrons 6,35,38,42,56,62, 72, 189 coagulationtime 244 collagen 99,244,245 cornea 39,41 coronary vessels 212,213 cylic AMP, see camp o desoxycholate 72 diet 17,19,28,100,112,113,, see also atherogenic diet dilinoleoyl PC 3,48,49,67 dimer forms of apoa-ii 22,26, 27 dimyristoyl PC 25,26 dipalmitoyl PC 39,87,94,95, distearyl lyso PI 75 distearyl PC 75 distearyl PI 75 dose effects 213,217 dyslipidemias 49, differential diagnosis 16 E egg yolk lecithin 40,191,206, 212 elaidic acid 162 elastic fibres 99 electron microscopy 35,41 electron spin resonance 87 electrophoresis 5,11,27,35,69 electroretinography 211,213, electrostatic interaction 37 endothelium, arterial 163,171, 175,180,214,217,247

3 251 endocytos is 171 enthalpy EPL, see polyenyl PC erythrocytes essential fatty acids 3,4, 141,246,247 essential phospholipids, see polyenyl PC excretion, biliary 77 F fat embolism 30 fatty acids 35,62,87,90, , 182 see individual compounds arterial wall 141,171, 173,175,179,182,203, chain elongation 141,171 fatty acid pattern, arterial lipids 147,148,171 PC 4,29,68,70,195 plasma lipids 98, , , , 195,213,221, platelet aggregation 247 fatty streak, see atherosclerotic lesions ,182 fibrous plaques, see atherosclerotic lesions fluidity, membrane 39,87,93-95,234 fluorescence spectroscopy 37 heart 54,58,89 hematocrit hemodynamics 30 hemolysis 70 heparin 123,190 hepatocytes 35,87,88 hydrophilic interaction 37 hydrophobic interaction 37,38 hyperbetalipoproteinemia 127 hypercholesterinemia 99, ,162,188,194 hyperemia, reactive , 241 hyperlipoproteinemia 11,12,20, 99,127,189,194 experimental 17,63,98-114, 188,192 type IIa 13-18,28,128, 130,244,245 type IIb 13-18,28,128, 130, type IV 13-15,17,18,28, hypertension 162 hypertriglyceridemia, experime n tal infiltrations 214,216 inositol 66,67 intestinal PC-pool 52,53,63 intestinal tract 53,78,89 G gas-chromotography 69,98,100 gas-liquid chromatography 81, 133,135,213 germination 67 glycerol 66,67,75,115,117,173 glycerol phosphate 75 glycerophosphorylcholine 55, 62 Golgi apparatu 35 H HDL 20-25,28,35-38,40-42, 81,82,98, ,109, 110,112,187,189 HDL deficiency, hereditary 39 HDL -subfractions 35,37,38 head groups 36,37,87,94 K Kennedy pathway 61 kidney 58,89 L LCAT-enzyme 29,34-42,85,131, 141,144,162,188,189,202, 203,207 activity 28,36,38,131,141, 144 substrate specifity 35,38 Tangier disease 40 LCAT deficiency, hereditary 34,38,41,133 LDL 23,29,35,38-40,81,82,98-100, ,131,187,189, 193 lecithin, see PC

4 252 lecithin, see egg yolk lecithin lipases 27,28,35,38,115,131, 187,189,190,195 linoleic acid, linoleate 3,4, 38,68,81,82,85,88,107,113, 130,143, ,244,245 linolenic acid 4,244 lipids, arterial metabolism 141,150, 158,160,163,173, 182,187,201 lipids, arterial synthesis 148,149,150,152,168,169 lipids, organs 28,58,63,89 lipids, plasma 11,18,28,107, 135 lipids, transport disorders 39 lipid-protein interaction 36,37,95 lipoproteins 5,6,11,16,20,27, 29,34-38,72,85,98,99,107, 1 13, 131,187, 1 89 see also apolipoproteins see also VLDL, LDL, HDL molecular structure 20,23-25,37,38 lipoprotein lipase 27,38,42, 113,122,190 lipoprotein-x 41 liposomes 38,39,87,94,95 LIPOSTABIL 11,28,80,82,123, 126,134,190,194,212,228, 229,234 liver 35,39,41,53,54,58,59, 73,76-78,87-89,113,158, 189, 190, 191, 193,213,219 LLAT 202 lungs 53,58,73,89 lymph 50,56,62 lymph cannulation 48,50,54,61 lymph nodes 39 lysolecithin, see lyso-pc lyso-pi 66,69,73-76,78 lyso-pi, toxicity 70 lyso-pc 13-16,36,38,41,66,69, 73-77, 1 7 1, 173, 176, I 80, 207,229 arterial wall 160,168,169, 183 platelet, aggregation 247, toxicity 70 lysophosphorylcholine 90 M membranes 34,87-96,133,179, 234 membranes fluidity 93,234 methyluracil 212 mice 66,70 micelles 36,37 microsomes 88,89,180 microcirculation 228,229, 234 mitochondria 88,89,171 mobility, molecular 94 monkeys, see species monomer form of apoa-ii 22,26,27 muscle 89 mucopolysaccharides 99 myocardial infarction 99 myocardium 158 myristic acid 175 N 13 NMR spectroscopy ( C) 37,38 norepinephrine 115,116 o oedema, sub-endothelial 161 oleic acid, oleate 4,38, ,130,143,158,162,173 -, arterial lipids p palmitic acid, palmitate 68, 107,113,128,173,175,193 perfusion technique, arterial 160,163,164,182 perifibrous lipid 161 ph-optima 204,205 phagocytosis 244 phosphate 66,67,75,154,173 phosphatidylcholine 13,14,16, 21,38,40,56,66,67,71,73 81,94,141, ,173, 201,202 see egg yolk lecithin see also polyenyl-pc (EPL) see diacyl-pcs lipoproteins molecular structure 3,4,11, 20,68,73 effect on lipases 27,28, 1 15, 162, effect on TG metabolism 28 phosphatidylethanolamine 13, 14,16,81,85

5 253 phosphatidylethanolymine, arterial wall 160,168, 169 phosphatidylinositol 13,14,16 66,67,152,154,173,179 -, pharmakokinetics 66,67,71-76,78 phosphatidylserine 13,14,16 -, arterial wall 160,168,169 phosphodiesterase 126 phospholipases 4,49,56,59 67,69,85, I 73, 180, I 87, 190, 191,194,202,206,208 phosholipids 20, ,37, 81,91,98,100,107,141,187, 20 I lipoproteins 4,11,19,35 plasma 11-13,15,17,81,128, 2 I 7 arterial wall 147, , 161,162,168,169 phospholipid pattern, lipoproteins 11,16,18-21 phosphoryl choline 55,90 pig 196,211,212 pigeons 162 platelets , ADP release 244 platelet aggregation test (PAT) 245 platelet factor III 244,247 polyenyl phosphatidylcholine (EPL) 3,4 absorption intestinal 49-56,61,63,77,247 arterial wall 29,141, , ,160,163, 169,170,171,178,183,187, 195,197,202 brain incorporation fatty acid composition 4, 29,68,70 intraduodenal injection 63,77,78 intraportal injection 58, 63,71,80 intravenous injection 63, 77,78,80,88,127,157,158, 202,212,229,234 lipoproteins 36-38,72 liver incorporation 54, 58,89,157,158 lymph 55,57,62 membrane incorporation 88-96,234 oral application 48,66,77, 87,98,127,211 pharmakokinetics 48-63, 66-79,80-86,89,158 plasma level 71,75,80,89 re-esterification (intestinal) 49,56,61,62,247 side effects 237 solution/suspension 71, 72,190 synthesis 49,67,75 therapy, long-time 127 effects on. -ACAT-enzyme 187,197 -atherosclerosis 28,30,49, 147,157, ,223,224 -blood flow 30, ,237, 241,243 -cerebral blood flow 237,242,243 -cholesterol, plasma 195,197 -cholesterylester hydrolase 175,187,194,195 -cholesterylester metabolism 29,141,148,158, 173,179,183,194,195,207 -erythrocytes FA metabolism, arterial wall 155,156,160,171, 173,178,183,202 -FA pattern, arterial lipids FA pattern, plasma lipids 98,100, ,130,134, fat embolism 30 hematocrit 229,230 -LCAT 144,148 -lipases 28,113,115,162, 187,189, lipids, arterial wall 140, ,158,163, ,183,202 -lipids, plasma 28-30, 52,63,76,100,113,127,128, 134,140,144, ,224 -lipoproteinlipase 113,162 -lipoprotein pattern 98,105, 106,127,131,217 -lyso-pc-turnover 179 -phospholipases 187,190, 191,194 -phospholipids, arterial wall ,158 -platelet aggregability proteins, arterial wall 147

6 254 -sterolester hydrolase 175 -transesterification of arterial lipids 141, 148,149,158,207 polyunsaturated, see polyenyl prebetalipoproteins 6 primates 20 prostaglandin E 245 protein-lipid interaction 87 protein-protein interaction 36 proteinuria 41 Q quails 196,212 R rabbits 123,140,141,160,162, 163,187,189,191,193,194, 196,211,212 radioimmunoassay 40 radiolabel exchange, body water 54,56,62 radiolabeling 49,67 rats 48,50,66,70,87,88,115, 116,192,196,212 rheologic parameters, see blood flow rhesus monkey 21-23,62 reticuloendothelial system 39,41 retinopathy, atherosclerotic 221 s saturation, acyls 36,87,107, 113,114,131,201,205,206, 219,221 scintillation counting 239,240 seasonal effects 13 sex differences 58,59,213,217, 218,221 side effects 237 soybeans 3,67,68 sphingomyelin 14,16,21,36-39, ,177 -, arterial wall 161 sphingomyelin hydrolase 173 sphingomyelin / PC ratio 13, 15-18,23 spin label 87,93,94 stearic acid, stearate 88,107, 113,244 sterol ester hydrolase 161, 162,175 substrate specifity 35,40,204 succinic acid 37,88 sucrose 17,18,112 sunflower 50 surface-activity 228 T Tangier disease 39 taurocholate 198 theophylline 115,116 therapy, long-time 12-15, ,244 thermostability, ATPases 91 thin-layer chromatography 69,76,81,98 thin-line protein 38 thiouracil 192 thrombocytes, see platelets thrombosis 247 tissue culture 41, ,148 tonsills 39 transesterification, Ch E 38,39,73,133,136 transfer-reaction, lipoproteins 36,38,133 triglycerides, plama 11,13,27, 77,98-102,112,113,128,135, 136,144,189,217 arterial wall ,177, 187 lipoproteins 38 lymph 56 metabolism 40,58,152 platelets 247, Tangier disease 39 triglyceride hydrolase 162, 177 u ultracentrifugation 5,11,23, 41,98,99 unsaturation, see saturation V vascular diseases 30,228,230, 233,234, viscosity, blood , plasma 228,229,234 VLDL 35,38,40,42,81,82,98,99, 100,107,113,133,189,193 X Xenon-clearance X-ray scattering

Lipoproteins Metabolism Reference: Campbell Biochemistry and Lippincott s Biochemistry

Lipoproteins Metabolism Reference: Campbell Biochemistry and Lippincott s Biochemistry Learning Objectives 1. Define lipoproteins and explain the rationale of their formation in blood. 2. List different